; and (2) encourage researchers and manufacturers that are authorized to produce or manufacture marijuana pursuant to section 303 of the Controlled Substances Act ( 21 U.S.C. 823 ), as amended by this Act, to comply with such guidelines to the extent applicable. (d) Definition In this section: (1) The term immature marijuana plant means a marijuana plant with no observable flowers or buds. (2) The term qualified medical marijuana researcher means a researcher who is registered to conduct research with marijuana under section 303(f)(3) of the Controlled Substances Act, as amended by section 3. 3. Facilitating marijuana research (a) In general Section 303(f) of the Controlled Substances Act ( 21 U.S.C. 823(f) ) is amended— (1) by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively; (2) by striking (f) The Attorney General and inserting (f)(1) The Attorney General ; (3) by striking Registration applications and inserting the following: (2) Registration applications ; (4) in paragraph (2), as so designated, by striking schedule I each place that term appears and inserting schedule I, except marijuana, ; (5) by striking Article 7 and inserting the following: (4) Article 7 ; and (6) by inserting before paragraph (4), as so designated, the following: (3) (A) The Attorney General shall register a practitioner to conduct research with marijuana if— (i) the applicant is authorized to dispense, or conduct research with respect to, controlled substances in schedules II, III, IV, and V under the laws of the State in which the applicant practices; (ii) the applicant is only using marijuana manufactured by a person registered under subsection (k); (iii) the applicant’s research protocol— (I) has been reviewed and allowed by— (aa) the Secretary under section 505(i) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(i) ); or (bb) the National Institutes of Health or another Federal agency that funds scientific research